Andere Sprachen ANI Pharmaceuticals, Inc.

Aktien

A1W15D

US00182C1036

ANIP

Pharmazeutika

Realtime-Estimate Cboe BZX Andere Börsenplätze 18:15:28 12.03.2026			% 5 Tage	Veränd. 1. Jan.
73.42 ^USD	-3.76%		-2.62%	-6.74%

11.03.	ANI Pharmaceuticals, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 03:00 PM
05.03.	Ani Pharmaceuticals: Insider verkauft Aktien im Wert von 552.031 US-Dollar laut aktueller SEC-Meldung	MT

Andere Sprachen

05.03.	Ani Pharmaceuticals Insider Sold Shares Worth $552,031, According to a Recent SEC Filing
03.03.	ANI Pharmaceuticals : Corporate Presentation March 2026
02.03.	ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance
27.02.	ANI Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
27.02.	Ani Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full Year 2026
27.02.	ANI Pharmaceuticals' Q4 Adjusted Earnings, Revenue Rise
27.02.	ANI: Q4 Earnings Snapshot
27.02.	(ANIP) ANI Pharmaceuticals Expects 2026 Revenue Range $1.06B - $1.12B, vs. FactSet Est of $1.01B
27.02.	(ANIP) ANI Pharmaceuticals Expects 2026 Adjusted EPS Range $8.83 - $9.34, vs. FactSet Est of $8.76
27.02.	Earnings Flash (ANIP) ANI Pharmaceuticals, Inc. Reports Q4 Revenue $247.1M, vs. FactSet Est of $231.1M
27.02.	Earnings Flash (ANIP) ANI Pharmaceuticals, Inc. Posts Q4 Adjusted EPS $2.33 per Share, vs. FactSet Est of $1.99
27.02.	ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance
24.02.	ANI Pharmaceuticals to Present at Upcoming Investor Conferences
13.02.	ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET
12.01.	Ani Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2026
12.01.	ANI Pharmaceuticals Reaffirms 2025 Outlook; Initiates 2026 Guidance
12.01.	(ANIP) ANI Pharmaceuticals Expects 2026 Revenue Range $1.06B - $1.12B, vs. FactSet Est of $955.1M
12.01.	ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities
06.01.	ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
02.12.	ANI Pharmaceuticals Announces Formation of FutureVision Advisory Council to Help Strategically Guide Ophthalmology and Retina Franchise
02.12.	ANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise
01.12.	ANI Pharmaceuticals announces board transition
01.12.	ANI Pharmaceuticals' Chairman Patrick Walsh to Retire; Thomas Haughey Named Successor
01.12.	ANI Pharmaceuticals Announces Board Transition
01.12.	Ani Pharmaceuticals, Inc. Announces Board Changes